Table 2.
Unadjusted relation between recurrence and patient, treatment, and tumour characteristics
| No recurrence | Recurrence | HR (95% CI) | p value | |
|---|---|---|---|---|
| n (%) | 90 (39) | 138 (61) | ||
| Age, median (IQR) | 65 (59–73) | 64 (55–70) | 0.98 (0.96–1.0) | 0.02 |
| Characteristics known before pelvic treatment | ||||
| Treatment period, n (%) | ||||
| 1969–1987 | 3 (33) | 6 (67) | 0.95 (0.37–2.5) | 0.92 |
| 1988–1993 | 9 (69) | 4 (31) | 0.27 (0.08–0.91) | 0.03 |
| 1994–2000 | 11 (37) | 19 (63) | 0.93 (0.51–1.7) | 0.81 |
| 2001–2012 | 56 (40) | 83 (60) | 0.75 (0.48–1.2) | 0.19 |
| 2013–2016 | 11 (30) | 26 (70) | Ref | |
| Moment of treatment, n (%) | ||||
| First treatment | 59 (38) | 95 (62) | Ref | |
| Recurrence treatment | 31 (42) | 43 (58) | 0.89 (0.62–1.3) | 0.56 |
| Main treatment modality, n (%) | ||||
| Chemoradiation | 7 (30) | 16 (70) | Ref | |
| Neoadjuvant chemotherapy | 15 (41) | 22 (59) | 0.71 (0.37–1.4) | 0.32 |
| Prophylactic PLND | 56 (39) | 86 (61) | 0.80 (0.47–1.4) | 0.43 |
| Therapeutic PLND | 10 (42) | 14 (58) | 0.84 (0.41–1.7) | 0.63 |
| Suspicious pelvic nodes on imaging, n (%) | ||||
| None | 19 (40) | 28 (60) | Ref | |
| Unilateral | 10 (22) | 35 (78) | 1.6 (0.97–2.6) | 0.067 |
| Bilateral | 9 (45) | 11 (55) | 0.89 (0.43–1.8) | 0.75 |
| Characteristics known after pelvic treatment | ||||
| Adjuvant radiotherapy, n (%) | ||||
| No | 71 (44) | 92 (56) | Ref | |
| Yes | 11 (27) | 30 (73) | 1.3 (0.86–2.0) | 0.21 |
| Differentiation, n (%) | ||||
| Good | 15 (44) | 19 (56) | Ref | |
| Intermediate | 44 (43) | 58 (57) | 1.1 (0.62–1.8) | 0.83 |
| Poor | 23 (30) | 54 (70) | 1.4 (0.80–2.4) | 0.25 |
| Pathological N stage, n (%) | ||||
| pN0 | 4 (100) | 0 (0) | ||
| pN1 | 13 (87) | 2 (13) | 0.10 (0.03–0.42) | 0.002 |
| pN2 | 18 (64) | 10 (36) | 0.28 (0.14–0.57) | <0.001 |
| pN3 | 33 (27) | 88 (73) | Ref | |
| pNx | 22 (37) | 38 (63) | 0.72 (0.49–1.1) | 0.11 |
| Pathology pelvic nodes, n (%) | ||||
| Negative | 66 (55) | 54 (45) | Ref | |
| Positive | 15 (21) | 58 (79) | 2.7 (1.8–3.9) | <0.001 |
| ENE, n (%) | ||||
| Absent | 51 (61) | 32 (39) | Ref | |
| Present | 35 (28) | 88 (72) | 2.6 (1.7–4.0) | <0.001 |
CI = confidence interval; HR = Hazard ratio; IQR = interquartile range; PLND = pelvic lymph node dissection; ENE = extranodal extension; Ref = reference.